Clinical Trials · NCT05714683
Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
- Phase
- N/A
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 600
- Start date
- Dec 2025
- Locations
- See registry
- Primary endpoint
- Number (Incidence) of adverse events (AEs)